Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.55 USD | -3.61% | +1.99% | -16.84% |
10/05 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
08/05 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.84% | 115.71Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.66% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 09, 2022